Covid, cold or flu?
11th November 2021
As viruses return with a vengeance, doctors are struggling to diagnose patients’ coughs and runny noses. In 1918 a deadly influenza pandemic swept the world, and doctors had a tough
As viruses return with a vengeance, doctors are struggling to diagnose patients’ coughs and runny noses. In 1918 a deadly influenza pandemic swept the world, and doctors had a tough
Last year, we were spared a strong wave of colds and flu – the numbers were far below the level of previous years1. And that’s no wonder: due to COVID-19
London-based infectious disease pharmaceutical company, Poolbeg Pharma, has announced their deal with testing and support specialist, Eurofins Genomics, according to Proactive Investors. CEO of Poolbeg Pharma, Jeremy Skillington, says that
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Poolbeg Pharma has a unique biomarker platform in development which may be used to identify those at risk of developing severe disease. Human challenge trials were conducted with front loaded
London-based infectious disease pharmaceutical company, Poolbeg Pharma, has announced their deal with testing and support specialist, Eurofins Genomics, according to Proactive Investors. CEO of Poolbeg Pharma, Jeremy Skillington, says that
Poolbeg Pharma’s Jeremy Skillington discusses their partnership with Eurofins Genomics, the ownership of the human challenge samples, the next steps in the data analysis programme, how AI analysis will be used to discover new drugs and the benefits of analysing the data through AI in this exclusive interview with DirectorsTalk.
Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has provided an update on new patent filings for its PredictViral™ platform that
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss partnering with leading global biopharma services company Eurofins Genomics. Jeremy tells us more about this exciting step in
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
